Ioflupane (123I)

N/A

Report date: 2025/11/25 17:06:19
NME

Base Information

Drug NameIoflupane (123I)
Drug Alias NameIoflupane I 123[123I]Ioflupaneβ-CIT-FPIoflupane I123Radio-labelled ioflupane +[10] 
ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Iodine > 123IDiagnostic agent (In vivo) > Radionuclide Imaging agent +[4] 
Mechanisms of ActionSingle-photon emission-computed tomography enhancers
TargetsNot applicable
Therapy Area/IndicationsDiagnostic agentsEssential TremorAlzheimer Disease +[11] 
Global Approved IndicationsDiagnostic agentsAlzheimer DiseaseParkinson Disease +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2000/07/27
Country/TerritoryUnited StatesSwedenGermany +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesGe Healthcare
China Registration ClassN/A

Develop Information

Active CompaniesNihon Medi-Physics Co LtdGe Healthcare BvGe Healthcare +[6] 
Inactive CompaniesDuke UniversityThe Institute For Neurodegenerative Disorders IncLund University
Active IndicationsDiagnostic agentsEssential TremorAlzheimer Disease +[9] 
Inactive IndicationsDementia, VascularCarcinoma, Renal Cell

Other Information

ATC CodeV09AB03
Related LinksWikipediaDrugBankKEGG